NCI Drug Dictionary
The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.
- cantuzumab ravtansine
An immunotoxin of a humanized monoclonal antibody C242 (MoAb HuC242) conjugated with a derivative of cytotoxic agent maytansine, DM4, with potential antitumor activity. Cantuzumab ravtansine is generated based on MoAb C242, which is raised against a cell surface superantigen, CA242, found in a variety of human tumor cells. Upon binding and entry, the immunoconjugate releases the maytansinoid agent DM4, which binds to tubulin, thereby affecting microtubule assembly/disassembly dynamics. As a result, this agent prevents cell division and reduces cell growth of cancer cells that express CA242. Check for active clinical trials using this agent. (NCI Thesaurus)
Synonym: maytansinoid DM4-conjugated humanized monoclonal antibody huC242 Code name: HuC242-DM4